瑋俊生物科技有限公司2025年下半年营收上升,净利润-6.0百万港元

公告速递
Feb 25

本期信息

瑋俊生物科技有限公司(股份代號:660)发布截至2025年12月31日止六个月的中期业绩预告,期内净亏损不超过6.0百万港元,相比2024年同期的约13.1百万港元,亏损幅度大幅收窄。公司方面指出,本期亏损显著减少主要得益于营业额的上升以及财务成本的下降。

业务分项

公告中强调,该集团在报告期内营收增长,带动整体业绩改善。同时,财务成本的减少也对盈利能力提升带来正面影响。由于公告未披露其他具体业务板块的营收或经营指标,暂未进一步拆分展示。

高管解读

(公告未提供相关高管原话)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10